John Mendelsohn

John Mendelsohn

UNVERIFIED PROFILE

Are you John Mendelsohn?   Register this Author

Register author
John Mendelsohn

John Mendelsohn

Publications by authors named "John Mendelsohn"

Are you John Mendelsohn?   Register this Author

61Publications

1643Reads

30Profile Views

Cooperative Effect of Oncogenic and in an HGF-Dominant Environment in Breast Cancer.

Mol Cancer Ther 2019 02 5;18(2):399-412. Epub 2018 Dec 5.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-18-0710DOI Listing
February 2019

Active Disclosure of Secondary Germline Findings to Deceased Research Participants' Personal Representatives: Process and Outcomes.

JCO Precis Oncol 2017 31;1. Epub 2017 Oct 31.

Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/po.17.00074DOI Listing
October 2017

Rare, Intense, Big fires dominate the global tropics under drier conditions.

Sci Rep 2017 10 30;7(1):14374. Epub 2017 Oct 30.

Research and Information Services of Namibia (RAISON), PO Box, 1405, Windhoek, Namibia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-017-14654-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662699PMC
October 2017

Clinical Use of Precision Oncology Decision Support.

JCO Precis Oncol 2017 13;2017. Epub 2017 Sep 13.

Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.17.00036DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179148PMC
September 2017

ALK: a tyrosine kinase target for cancer therapy.

Cold Spring Harb Mol Case Stud 2017 Jan;3(1):a001115

Department of Thoracic/Head and Neck, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/mcs.a001115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5171696PMC
January 2017

Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis.

JAMA Oncol 2016 Nov;2(11):1452-1459

Center for Personalized Cancer Therapy, Division of Hematology and Oncology, University of California, San Diego3Worldwide Innovative Network for Personalized Cancer Therapy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.2129DOI Listing
November 2016

Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel.

Oncotarget 2016 Nov;7(44):71686-71695

Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.11994DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342111PMC
November 2016

Commentary on "Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts" (A Follow Up).

Authors:
John Mendelsohn

Cancer Res 2016 09;76(18):5192-4

Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-54
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-16-2269DOI Listing
September 2016

Reply to M.P. Decatris et al.

J Clin Oncol 2016 Mar 11;34(8):886. Epub 2016 Jan 11.

The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.2479DOI Listing
March 2016

Response.

J Natl Cancer Inst 2016 Mar 24;108(3):djw001. Epub 2016 Feb 24.

Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA, USA (MS and RZ); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA (JJL and CW); The University of Texas MD Anderson Cancer Center, Houston, USA (JM); American Society of Clinical Oncology, Alexandria, VA, USA (RLS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw001DOI Listing
March 2016

The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform.

Drug Discov Today 2015 Dec 3;20(12):1433-8. Epub 2015 Jul 3.

Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drudis.2015.05.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648066PMC
December 2015

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.

J Clin Oncol 2015 Nov 24;33(32):3817-25. Epub 2015 Aug 24.

Maria Schwaederle, Melissa Zhao, and Razelle Kurzrock, Center for Personalized Cancer Therapy, University of California, San Diego, Moores Cancer Center, La Jolla, CA; J. Jack Lee and John Mendelsohn, The University of Texas MD Anderson Cancer Center, Houston, TX; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Alexander M. Eggermont and Vladimir Lazar, Institut Gustave Roussy, University Paris-Sud; and Alexander M. Eggermont, Richard L. Schilsky, John Mendelsohn, Vladimir Lazar, and Razelle Kurzrock, Worldwide Innovative Network in Personalized Cancer Medicine, Villejuif, France.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/32/3817.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.61.5997
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.61.5997DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737863PMC
November 2015

Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.

J Natl Cancer Inst 2015 Nov 15;107(11). Epub 2015 Sep 15.

Department of Clinical Medicine, Hemocentro da Unicamp, University of Campinas, Sao Paulo, Brazil (DLFJ); Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DLFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA (MS, RK); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX (CW, JJL); Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX (DSH); Department of Functional Genomics, Institut Gustave Roussy, University Paris-Sud, Villejuif, France (AME, VL); Worldwide Innovative Network in Personalized Cancer Medicine, Villejuif, France (AME, RLS, JM, VL, RK); American Society of Clinical Oncology, Alexandria, VA (RLS); The University of Texas MD Anderson Cancer Center, Houston, TX (JM).

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/107/11/djv253.full.pd
Web Search
http://jnci.oxfordjournals.org/content/108/3/djv430.full.pdf
Web Search
http://jnci.oxfordjournals.org/lookup/doi/10.1093/jnci/djv25
Publisher Site
http://dx.doi.org/10.1093/jnci/djv253DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857149PMC
November 2015

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Authors:
Ayalew Tefferi Hagop Kantarjian S Vincent Rajkumar Lawrence H Baker Jan L Abkowitz John W Adamson Ranjana Hira Advani James Allison Karen H Antman Robert C Bast John M Bennett Edward J Benz Nancy Berliner Joseph Bertino Ravi Bhatia Smita Bhatia Deepa Bhojwani Charles D Blanke Clara D Bloomfield Linda Bosserman Hal E Broxmeyer John C Byrd Fernando Cabanillas George Peter Canellos Bruce A Chabner Asher Chanan-Khan Bruce Cheson Bayard Clarkson Susan L Cohn Gerardo Colon-Otero Jorge Cortes Steven Coutre Massimo Cristofanilli Walter J Curran George Q Daley Daniel J DeAngelo H Joachim Deeg Lawrence H Einhorn Harry P Erba Francisco J Esteva Elihu Estey Isaiah J Fidler James Foran Stephen Forman Emil Freireich Charles Fuchs James N George Morie A Gertz Sergio Giralt Harvey Golomb Peter Greenberg Jordan Gutterman Robert I Handin Samuel Hellman Paulo Marcelo Hoff Ronald Hoffman Waun Ki Hong Mary Horowitz Gabriel N Hortobagyi Clifford Hudis Jean Pierre Issa Bruce Evan Johnson Philip W Kantoff Kenneth Kaushansky David Khayat Fadlo R Khuri Thomas J Kipps Margaret Kripke Robert A Kyle Richard A Larson Theodore S Lawrence Ross Levine Michael P Link Scott M Lippman Sagar Lonial Gary H Lyman Maurie Markman John Mendelsohn Neal J Meropol Yoav Messinger Therese M Mulvey Susan O'Brien Roman Perez-Soler Raphael Pollock Josef Prchal Oliver Press Jerald Radich Kanti Rai Saul A Rosenberg Jacob M Rowe Hope Rugo Carolyn D Runowicz Brenda M Sandmaier Alan Saven Andrew I Schafer Charles Schiffer Mikkael A Sekeres Richard T Silver Lillian L Siu David P Steensma F Marc Stewart Wendy Stock Richard Stone Rainer Storb Louise C Strong Martin S Tallman Michael Thompson Naoto T Ueno Richard A Van Etten Julie M Vose Peter H Wiernik Eric P Winer Anas Younes Andrew D Zelenetz Charles A LeMaistre

Mayo Clin Proc 2015 Aug 23;90(8):996-1000. Epub 2015 Jul 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2015.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365030PMC
August 2015

A decision support framework for genomically informed investigational cancer therapy.

J Natl Cancer Inst 2015 Jul 11;107(7). Epub 2015 Apr 11.

Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy , the University of Texas MD Anderson Cancer Center, Houston, TX (FMB, AJ, VH, AMB, JZ, KRS, JM, GBM); Departments of Investigational Cancer Therapeutics (FMB, LB, SAPP, DSH, AMT), Surgical Oncology (FMB), Hematopathology (MR, KPP), Bioinformatics & Computational Biology (KC), GI Medical Oncology (SK), Melanoma Medical Oncology (MAD), Experimental Therapeutics (RB), Systems Biology (AKE, GBM), the University of Texas MD Anderson Cancer Center, Houston, TX; School of Biomedical Informatics, the University of Texas Health Science Center, Houston, TX (EVB).

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/107/7/djv098.full.pdf
Web Search
http://jnci.oxfordjournals.org/cgi/doi/10.1093/jnci/djv098
Publisher Site
http://dx.doi.org/10.1093/jnci/djv098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651038PMC
July 2015

Innovative clinical trials for development of personalized cancer medicine.

Mol Oncol 2015 May 5;9(5):933-4. Epub 2015 Mar 5.

ASCO, American Society of Clinical Oncology, Alexandria, VA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2015.02.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528749PMC
May 2015

CCR 20th anniversary commentary: a chimeric antibody, C225, inhibits EGFR activation and tumor growth.

Clin Cancer Res 2015 Jan;21(2):227-9

Helio Genetics, East Hanover, New Jersey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2491DOI Listing
January 2015

The 2010 Institute of Medicine consensus statement "A national clinical trials network for the 21st century": progress and challenges.

Semin Oncol 2014 Aug 11;41(4):435-436. Epub 2014 Jun 11.

Dana-Farber/Brigham and Women's Cancer Center, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2014.06.003DOI Listing
August 2014

Turning the tide against cancer through sustained medical innovation: the pathway to progress.

Clin Cancer Res 2014 Mar 12;20(5):1081-6. Epub 2014 Feb 12.

Authors' Affiliations: Center for Learning Healthcare, Duke Cancer Center Research Program, Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina; Personalized Medicine Coalition; and Pharmaceutical Research and Manufacturers of America, Washington, DC; Complex Adaptive Systems Initiative, School of Life Sciences, Arizona State University, Tucson, Arizona; M2Gen, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center, Tampa, Florida; American Association for Cancer Research, Philadelphia, Pennsylvania; Opus Three LLC, Rockville, Maryland; Clinical Development and Medical Affairs, Eli Lilly and Company, Indianapolis, Indiana; Feinstein Kean Healthcare, Cambridge, Massachusetts; Global Strategic Market Access and Policy, Celgene Corporation, Summit, New Jersey; American Cancer Society, Atlanta, Georgia; The Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas; and Breast Oncology Program, Applied Genomics, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-3430DOI Listing
March 2014

Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps.

Discov Med 2014 Feb;17(92):101-14

Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160907PMC
February 2014

Personalizing oncology: perspectives and prospects.

Authors:
John Mendelsohn

J Clin Oncol 2013 May 15;31(15):1904-11. Epub 2013 Apr 15.

The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 491, Houston, TX 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.45.3605DOI Listing
May 2013

Building a personalized medicine infrastructure at a major cancer center.

J Clin Oncol 2013 May 15;31(15):1849-57. Epub 2013 Apr 15.

University of Texas MD Anderson Cancer Center, 1400 Pressler St, FCT17.5030, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.45.3043DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878103PMC
May 2013

The impact of tumor heterogeneity on patient treatment decisions.

Clin Chem 2013 Jan 9;59(1):38-40. Epub 2012 Nov 9.

Sheikh Khalifa bin Zayed Al Nahyan Institute of Personalized Cancer Therapy-IPCT, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://www.clinchem.org/cgi/doi/10.1373/clinchem.2012.194712
Publisher Site
http://dx.doi.org/10.1373/clinchem.2012.194712DOI Listing
January 2013

Bioinformatics and systems biology.

Mol Oncol 2012 Apr 17;6(2):147-54. Epub 2012 Feb 17.

Department of Systems Biology, Institute for Personalized Cancer Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX 77054, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2012.01.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3345061PMC
April 2012

WIN Consortium--challenges and advances.

Nat Rev Clin Oncol 2011 Mar;8(3):133-4

The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2010.230DOI Listing
March 2011

A national cancer clinical trials system for targeted therapies.

Authors:
John Mendelsohn

Sci Transl Med 2011 Mar;3(75):75cm8

University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.3001716DOI Listing
March 2011

Shaking up cancer clinical trials: an interview with John Mendelsohn, M.D., by Joanne Nicholas.

Authors:
John Mendelsohn

J Natl Cancer Inst 2010 Aug 6;102(16):1219-21. Epub 2010 Aug 6.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djq320DOI Listing
August 2010

From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway.

Proc Natl Acad Sci U S A 2010 Mar 26;107(11):5118-23. Epub 2010 Feb 26.

David H Koch Center, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0915146107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841862PMC
March 2010

Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer.

Clin Genitourin Cancer 2009 Oct;7(3):E77-82

Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S155876731170035
Publisher Site
http://dx.doi.org/10.3816/CGC.2009.n.028DOI Listing
October 2009

EGF receptors as a target for cancer therapy.

Authors:
John Mendelsohn

Trans Am Clin Climatol Assoc 2004 ;115:249-53; discussion 253-4

The University of Texas MD Anderson Cancer Center,Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2263769PMC
April 2009

Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab.

Mol Cancer Ther 2008 May;7(5):1207-17

Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Unit 036, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-07
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-07-2187DOI Listing
May 2008

Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.

Cancer Res 2007 Sep;67(17):8240-7

Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-07-0589DOI Listing
September 2007

Circulating tumor cells in breast cancer: Advanced tools for "tailored" therapy?

Proc Natl Acad Sci U S A 2006 Nov 7;103(46):17073-4. Epub 2006 Nov 7.

The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0608651103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1859890PMC
November 2006

Epidermal growth factor receptor targeting in cancer.

Semin Oncol 2006 Aug;33(4):369-85

The University of Texas, MD Anderson Cancer Center, Houston, TX 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2006.04.003DOI Listing
August 2006

The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression.

Oncogene 2005 Jun;24(27):4433-41

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 036, 1515 Holcombe Blvd., Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1208625DOI Listing
June 2005

The role of growth factor signaling in malignancy.

Cancer Treat Res 2003 ;115:19-72

University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/0-306-48158-8_2DOI Listing
July 2003

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.

J Clin Oncol 2003 Jul;21(14):2787-99

University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2003.01.504DOI Listing
July 2003

Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic.

Authors:
John Mendelsohn

Cancer Immunol Immunother 2003 May 14;52(5):342-6. Epub 2003 Mar 14.

The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-002-0354-7DOI Listing
May 2003

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

Oncogene 2003 May;22(21):3205-12

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1206394DOI Listing
May 2003

Targeting the epidermal growth factor receptor for cancer therapy.

Authors:
John Mendelsohn

J Clin Oncol 2002 Sep;20(18 Suppl):1S-13S

University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA.

View Article

Download full-text PDF

Source
September 2002